查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1460658

围产期感染市场 - 全球产业规模、份额、趋势、机会和预测，按感染类型、治疗、诊断、最终用户、地区和竞争细分，2019-2029F

Perinatal Infections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Infection Type, By Treatment, By Diagnosis, By End user, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年，全球围产期感染市场估值为 15.2 亿美元，预计到 2029 年，预测期内将稳定成长，复合CAGR为5.25%。围产期感染，通常称为新生儿感染，为一个重大的全球健康问题。怀孕期间或出生后不久发生的感染对母亲和新生儿都构成重大风险。全球围产期感染市场在诊断、预防和治疗这些感染方面发挥着至关重要的作用，最终有助于增强孕产妇和新生儿的健康。围产期感染包括一系列病症，从母体感染到新生儿产后感染，由细菌、病毒或真菌引起，影响母婴单位的各个部位。

人们对早期发现和治疗围产期感染重要性的认识不断提高，推动了对诊断服务和改善医疗基础设施的需求。世界各地的医疗保健系统正在投资新生儿护理单位和母胎医学，以有效解决围产期感染问题，特别是在资源匮乏的环境中，感染率仍然令人担忧，导致新生儿发病率和死亡率。

技术的进步彻底改变了围产期感染的诊断，快速检测和更准确的诊断工具可以实现早期检测和更好的患者治疗结果。製药和生物技术产业积极参与新疗法和疫苗的研究和开发，透过开发有前景的产品推动市场成长。

主要市场驱动因素

围产期感染盛行率上升正在推动全球围产期感染市场

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球围产期感染市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依感染类型（鉅细胞病毒感染、肠病毒感染、生殖器疱疹、淋病、人类免疫缺乏病毒、李斯特菌病、淋巴球脉络膜脑膜炎病毒、德国麻疹、梅毒、水痘等）
    • 依治疗（抗生素、抗病毒药物、抗爱滋病毒药物、其他）
    • 透过诊断（孕产妇检查、新生儿检查、其他）
    • 按最终使用者（医院、诊所、门诊护理中心、其他）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图
    • 按感染类型
    • 按治疗
    • 透过诊断
    • 按最终用户
    • 按地区

第 5 章：亚太地区围产期感染市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 按感染类型
    • 按治疗
    • 透过诊断
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 6 章：欧洲围产期感染市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 按感染类型
    • 按治疗
    • 透过诊断
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美围产期感染市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 按感染类型
    • 按治疗
    • 透过诊断
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲围产期感染市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 按感染类型
    • 按治疗
    • 透过诊断
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲围产期感染市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 按感染类型
    • 按治疗
    • 透过诊断
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势发展

  • 最近的发展
  • 产品发布
  • 併购

第 12 章：全球围产期感染市场：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Merck KGaA
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories, Inc
  • Hologic Inc.
  • Gilead Sciences, Inc.
  • Emcure Pharmaceuticals Limited.
  • Cipla Inc.
  • Bausch Health Companies Inc
  • Johnson Johnson
  • Teva Pharmaceutical Industries Ltd.

第 15 章：策略建议

第 16 章：关于我们免责声明

简介目录
Product Code: 20969

Global Perinatal Infections Market was valued at USD 1.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Perinatal infections, often referred to as neonatal infections, are a significant global health concern.Perinatal infections, occurring during pregnancy or shortly after birth, pose significant risks to both mothers and newborns. The global market for perinatal infections plays a vital role in diagnosing, preventing, and treating these infections, ultimately contributing to enhanced maternal and neonatal health. Perinatal infections encompass a range of conditions, from maternal infections to postnatal infections in newborns, caused by bacteria, viruses, or fungi, affecting various parts of the maternal-fetal unit.

Increased awareness about the importance of early detection and treatment of perinatal infections has driven demand for diagnostic services and improved healthcare infrastructure. Healthcare systems worldwide are investing in neonatal care units and maternal-fetal medicine to address perinatal infections effectively, particularly in low-resource settings where prevalence remains a concern, leading to neonatal morbidity and mortality.

Advancements in technology have revolutionized the diagnosis of perinatal infections, with rapid tests and more accurate diagnostic tools enabling early detection and better patient outcomes. The pharmaceutical and biotechnology sectors are actively involved in researching and developing new therapies and vaccines, driving market growth with promising products in development.

Key Market Drivers

Rising Prevalence of Perinatal Infections is Driving the Global Perinatal Infections Market

Perinatal infections, which encompass infections occurring during pregnancy, childbirth, and the postpartum period, have emerged as a significant concern in the field of maternal and child health. The increasing prevalence of perinatal infections worldwide is driving the growth of the global perinatal infections market. These infections pose a serious threat to both the mother and the newborn, emphasizing the need for enhanced prevention, diagnosis, and treatment strategies.Perinatal infections can occur at any stage of pregnancy or during labor and delivery, putting the health and well-being of both the mother and her newborn at risk. Common perinatal infections include group B Streptococcus (GBS), chlamydia, syphilis, human immunodeficiency virus (HIV), and hepatitis B. These infections can lead to severe complications, such as preterm birth, low birth weight, neonatal sepsis, congenital anomalies, and maternal morbidity and mortality.

Several factors contribute to the increasing prevalence of perinatal infections. Inadequate access to prenatal care and limited healthcare resources in certain regions result in undiagnosed or untreated infections. Regular prenatal care visits are essential for screening and early detection of perinatal infections.Certain high-risk behaviors, such as substance abuse, unprotected sexual activity, and multiple sexual partners, increase the risk of contracting perinatal infections. Addressing these behaviors through education and prevention programs is crucial.Global migration trends have led to a rise in maternal migration, making it challenging to provide consistent care to pregnant women and track their infection status.The emergence of antibiotic-resistant strains of bacteria has made the treatment of perinatal infections more complex, necessitating the development of alternative therapies.

Growing Healthcare Expenditure is Driving the Global Perinatal Infections Market

Perinatal infections, which impact pregnant women, fetuses, and newborns, have garnered heightened attention due to their significant effects on maternal and infant health. The global market for perinatal infections is expanding, primarily driven by increased healthcare spending and a greater focus on maternal and child healthcare. A key driver of this market growth is the notable rise in healthcare expenditure worldwide, leading to enhanced maternal and child healthcare services. This increased investment has spurred the development of innovative diagnostic tools, vaccines, and treatments for perinatal infections.

The trend of women delaying childbirth for educational and career pursuits has resulted in a higher maternal age, associated with elevated risks of perinatal infections and complications. Consequently, there is a growing demand for specialized healthcare services and interventions to address this demographic shift, further propelling the perinatal infections market. Recent advancements in diagnostic methods have led to more accurate and timely testing, facilitating early detection and intervention, thereby reducing transmission risks from mother to child. Similarly, improved treatment options have yielded better outcomes for both mothers and infants, driving increased investment in perinatal healthcare.

Public awareness campaigns about perinatal infections and the importance of prenatal care have contributed to rising demand for related services and treatments. Government health policies and initiatives aimed at enhancing maternal and child healthcare have also played a crucial role in driving market growth. Investments in infrastructure, research, and preventive measures, along with subsidies for healthcare services, have encouraged healthcare providers to expand their offerings in this domain.The growing perinatal infections market presents significant implications for healthcare systems globally. As healthcare spending continues to increase, perinatal care is increasingly recognized as a vital aspect of healthcare services. Governments, healthcare providers, and organizations are prioritizing preventive measures, early detection, and treatment to improve outcomes for mothers and infants. However, this growth poses challenges, including the strain on existing healthcare infrastructure due to the rising demand for specialized perinatal care services. Healthcare systems must adapt by investing in training, staffing, and infrastructure development to meet evolving needs effectively.

Key Market Challenges

Limited Awareness and Education

One of the fundamental challenges in addressing perinatal infections is the lack of awareness and education among pregnant individuals, healthcare professionals, and the general public. Many people do not fully understand the risks associated with perinatal infections, how they can be prevented, and the importance of early diagnosis and treatment. This lack of awareness can lead to delayed or inadequate care, exacerbating the problem.

Access to Healthcare

Access to quality healthcare is a critical issue in many parts of the world. In low-income and underserved areas, pregnant individuals may struggle to access prenatal care, including routine screenings and testing for perinatal infections. This lack of access can result in undiagnosed infections that could have been managed or treated effectively if detected early.

Cost of Diagnostics and Treatment

The cost of diagnostic tests and treatment for perinatal infections can be prohibitively high, particularly in regions with limited healthcare resources. This financial barrier can prevent pregnant individuals from seeking proper care and hinder healthcare systems from implementing comprehensive screening and treatment programs.

Antimicrobial Resistance

Perinatal infections are often treated with antibiotics, but the rising problem of antimicrobial resistance poses a significant challenge. As bacteria become resistant to commonly used antibiotics, the effectiveness of treatment options diminishes. This requires the development of new and more expensive drugs, putting further strain on healthcare budgets.

Stigma and Cultural Beliefs

Stigma and cultural beliefs surrounding perinatal infections can lead to delayed diagnosis and treatment. In some cultures, there may be a reluctance to seek medical help due to fear of discrimination or social exclusion. This can have severe consequences on the health of both the pregnant individual and the newborn.

Inadequate Surveillance and Reporting

Accurate data collection and reporting of perinatal infections are crucial for understanding the scope of the problem and implementing effective public health interventions. In many regions, there is a lack of systematic surveillance and reporting systems, making it challenging to assess the prevalence and trends of perinatal infections.

Global Health Inequalities

The global distribution of perinatal infections is highly uneven, with low- and middle-income countries experiencing a disproportionate burden of the disease. This highlights the broader issue of global health inequalities, as limited resources and infrastructure hinder the ability to address perinatal infections effectively.

Vertical Transmission

Vertical transmission, where the infection is passed from mother to child during pregnancy, delivery, or breastfeeding, is a significant challenge. Preventing these modes of transmission requires a multifaceted approach that includes antenatal care, safe delivery practices, and the promotion of breastfeeding, which may be difficult to implement in certain settings.

Key Market Trends

Technological Advancements

Early and precise diagnosis of perinatal infections is pivotal for effective management and treatment. Recent technological advancements have significantly transformed the diagnostic landscape, facilitating quicker and more accurate detection of these infections.

Next-Generation Sequencing (NGS) has revolutionized genomics, enabling rapid and comprehensive analysis of microbial DNA in clinical samples. This technology empowers healthcare providers to swiftly identify pathogens responsible for perinatal infections. Point-of-Care Testing (POCT) devices offer on-site testing, delivering rapid results crucial for timely interventions during childbirth or neonatal care. Polymerase Chain Reaction (PCR) and other molecular diagnostic techniques have become more accessible and efficient, ensuring high-precision detection of perinatal infections.

Advanced technology has also revolutionized the treatment of perinatal infections. Molecular diagnostics enable the identification of specific pathogens and their susceptibilities, facilitating targeted antibiotic therapies to minimize drug resistance and side effects. Neonatal Intensive Care Units (NICUs) have been equipped with state-of-the-art medical devices, ensuring optimal care for newborns with perinatal infections. Telemedicine has expanded healthcare access, particularly in underserved areas, allowing for expert consultations in complicated cases of perinatal infections.

Technological innovations have enabled the collection and analysis of extensive data on perinatal infections. This data-driven approach enhances understanding of infection epidemiology, risk factors, and the development of predictive models. Artificial intelligence and machine learning support informed decision-making and the implementation of preventive strategies by healthcare providers.

Segmental Insights

Infection Type Insights

Basedon the category of Infection Type, Human Immunodeficiency Virus emerged as the dominant player in the global market for Perinatal Infections in 2023.Perinatal infections, which are infections that are transmitted from mother to child during pregnancy, childbirth, or breastfeeding, can have severe consequences for the health and well-being of both mother and child. These infections can result in preterm birth, low birth weight, developmental issues, and even death. In the global perinatal infections market, addressing and controlling these infections is a top priority for healthcare professionals and policymakers.

Perinatal HIV infection can lead to numerous health challenges for the infected child. These include an increased risk of opportunistic infections, developmental delays, and even premature death. In response to the threat posed by HIV in perinatal infections, global health organizations and governments have implemented strategies to mitigate its impact.

End user Insights

The Hospitals Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are equipped with state-of-the-art diagnostic tools and facilities. This enables healthcare professionals to accurately and swiftly diagnose perinatal infections in both the mother and the newborn. Early diagnosis is crucial in preventing the spread of infection and initiating timely treatment, which can significantly improve outcomes for the patients. Perinatal infections require specialized care and a multidisciplinary approach. Hospitals and clinics have specialized departments and medical staff, including neonatologists, obstetricians, and infectious disease specialists, who collaborate to provide comprehensive care to affected individuals. This collaborative approach is vital in managing complex cases of perinatal infections.

Regional Insights

North America emerged as the dominant player in the global Perinatal Infections market in 2023, holding the largest market share in terms of value. North America boasts a highly developed healthcare infrastructure with state-of-the-art facilities, specialized medical practitioners, and advanced technology. This infrastructure enables swift and accurate diagnosis and treatment of perinatal infections, thereby fueling the market's growth. The region's high healthcare standards do not negate the prevalence of perinatal infections. North America is still experiencing a significant number of cases, creating a steady demand for diagnostics, treatments, and preventive measures.

Key Market Players

Merck KGaA

Beckman Coulter Inc.

Bio-Rad Laboratories, Inc

Hologic Inc.

Gilead Sciences, Inc.

Emcure Pharmaceuticals Limited.

Cipla Inc.

Bausch Health Companies Inc

Johnson Johnson

Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Perinatal Infections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Perinatal Infections Market,By Infection Type:

  • Natural
  • Synthetic
  • Cytomegalovirus Infection
  • Enterovirus Infection
  • Genital Herpes
  • Gonorrhoea
  • Human Immunodeficiency Virus
  • Listeriosis Lymphocytic Choriomeningitis Virus
  • Rubella
  • Syphilis
  • Varicella
  • Others

Perinatal Infections Market,By Treatment:

  • Antibiotics
  • Antiviral
  • Antiretroviral
  • Others

Perinatal Infections Market,By Diagnosis:

  • Maternal Test
  • Neonatal Test
  • Others

Perinatal Infections Market,By End use:

  • Hospitals Clinics
  • Ambulatory Care Centers
  • Others

Perinatal Infections Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Perinatal Infections Market.

Available Customizations:

Global Perinatal Infections market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Perinatal Infections Market Outlook

  • 4.1.Market Size Forecast
    • 4.1.1.By Value
  • 4.2.Market Share Forecast
    • 4.2.1.By Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Listeriosis Lymphocytic Choriomeningitis Virus, Rubella, Syphilis, Varicella, Others)
    • 4.2.2.By Treatment (Antibiotics, Antiviral, Antiretroviral, Others)
    • 4.2.3.By Diagnosis (Maternal Test, Neonatal Test, Others)
    • 4.2.4.By End user (Hospitals Clinics,Ambulatory Care Centers, Others)
    • 4.2.5.By Region
    • 4.2.6.By Company (2023)
  • 4.3.Market Map
    • 4.3.1.By Infection Type
    • 4.3.2.By Treatment
    • 4.3.3.By Diagnosis
    • 4.3.4.By End user
    • 4.3.5.By Region

5.Asia Pacific Perinatal Infections Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Infection Type
    • 5.2.2.By Treatment
    • 5.2.3.By Diagnosis
    • 5.2.4.By End user
    • 5.2.5.By Country
  • 5.3.Asia Pacific: Country Analysis
    • 5.3.1.China Perinatal Infections Market Outlook
      • 5.3.1.1.Market Size Forecast
        • 5.3.1.1.1.By Value
      • 5.3.1.2.Market Share Forecast
        • 5.3.1.2.1.By Infection Type
        • 5.3.1.2.2.By Treatment
        • 5.3.1.2.3.By Diagnosis
        • 5.3.1.2.4.By End user
    • 5.3.2.India Perinatal Infections Market Outlook
      • 5.3.2.1.Market Size Forecast
        • 5.3.2.1.1.By Value
      • 5.3.2.2.Market Share Forecast
        • 5.3.2.2.1.By Infection Type
        • 5.3.2.2.2.By Treatment
        • 5.3.2.2.3.By Diagnosis
        • 5.3.2.2.4.By End user
    • 5.3.3.Australia Perinatal Infections Market Outlook
      • 5.3.3.1.Market Size Forecast
        • 5.3.3.1.1.By Value
      • 5.3.3.2.Market Share Forecast
        • 5.3.3.2.1.By Infection Type
        • 5.3.3.2.2.By Treatment
        • 5.3.3.2.3.By Diagnosis
        • 5.3.3.2.4.By End user
    • 5.3.4.Japan Perinatal Infections Market Outlook
      • 5.3.4.1.Market Size Forecast
        • 5.3.4.1.1.By Value
      • 5.3.4.2.Market Share Forecast
        • 5.3.4.2.1.By Infection Type
        • 5.3.4.2.2.By Treatment
        • 5.3.4.2.3.By Diagnosis
        • 5.3.4.2.4.By End user
    • 5.3.5.South Korea Perinatal Infections Market Outlook
      • 5.3.5.1.Market Size Forecast
        • 5.3.5.1.1.By Value
      • 5.3.5.2.Market Share Forecast
        • 5.3.5.2.1.By Infection Type
        • 5.3.5.2.2.By Treatment
        • 5.3.5.2.3.By Diagnosis
        • 5.3.5.2.4.By End user

6.Europe Perinatal Infections Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Infection Type
    • 6.2.2.By Treatment
    • 6.2.3.By Diagnosis
    • 6.2.4.By End user
    • 6.2.5.By Country
  • 6.3.Europe: Country Analysis
    • 6.3.1.France Perinatal Infections Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Infection Type
        • 6.3.1.2.2.By Treatment
        • 6.3.1.2.3.By Diagnosis
        • 6.3.1.2.4.By End user
    • 6.3.2.Germany Perinatal Infections Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Infection Type
        • 6.3.2.2.2.By Treatment
        • 6.3.2.2.3.By Diagnosis
        • 6.3.2.2.4.By End user
    • 6.3.3.Spain Perinatal Infections Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Infection Type
        • 6.3.3.2.2.By Treatment
        • 6.3.3.2.3.By Diagnosis
        • 6.3.3.2.4.By End user
    • 6.3.4.Italy Perinatal Infections Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Infection Type
        • 6.3.4.2.2.By Treatment
        • 6.3.4.2.3.By Diagnosis
        • 6.3.4.2.4.By End user
    • 6.3.5.United Kingdom Perinatal Infections Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Infection Type
        • 6.3.5.2.2.By Treatment
        • 6.3.5.2.3.By Diagnosis
        • 6.3.5.2.4.By End user

7.North America Perinatal Infections Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Infection Type
    • 7.2.2.By Treatment
    • 7.2.3.By Diagnosis
    • 7.2.4.By End user
    • 7.2.5.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Perinatal Infections Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Infection Type
        • 7.3.1.2.2.By Treatment
        • 7.3.1.2.3.By Diagnosis
        • 7.3.1.2.4.By End user
    • 7.3.2.Mexico Perinatal Infections Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Infection Type
        • 7.3.2.2.2.By Treatment
        • 7.3.2.2.3.By Diagnosis
        • 7.3.2.2.4.By End user
    • 7.3.3.Canada Perinatal Infections Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Infection Type
        • 7.3.3.2.2.By Treatment
        • 7.3.3.2.3.By Diagnosis
        • 7.3.3.2.4.By End user

8.South America Perinatal Infections Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Infection Type
    • 8.2.2.By Treatment
    • 8.2.3.By Diagnosis
    • 8.2.4.By End user
    • 8.2.5.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Perinatal Infections Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Infection Type
        • 8.3.1.2.2.By Treatment
        • 8.3.1.2.3.By Diagnosis
        • 8.3.1.2.4.By End user
    • 8.3.2.Argentina Perinatal Infections Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Infection Type
        • 8.3.2.2.2.By Treatment
        • 8.3.2.2.3.By Diagnosis
        • 8.3.2.2.4.By End user
    • 8.3.3.Colombia Perinatal Infections Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Infection Type
        • 8.3.3.2.2.By Treatment
        • 8.3.3.2.3.By Diagnosis
        • 8.3.3.2.4.By End user

9.Middle East and Africa Perinatal Infections Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Infection Type
    • 9.2.2.By Treatment
    • 9.2.3.By Diagnosis
    • 9.2.4.By End user
    • 9.2.5.By Country
  • 9.3.MEA: Country Analysis
    • 9.3.1.South Africa Perinatal Infections Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Infection Type
        • 9.3.1.2.2.By Treatment
        • 9.3.1.2.3.By Diagnosis
        • 9.3.1.2.4.By End user
    • 9.3.2.Saudi Arabia Perinatal Infections Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Infection Type
        • 9.3.2.2.2.By Treatment
        • 9.3.2.2.3.By Diagnosis
        • 9.3.2.2.4.By End user
    • 9.3.3.UAE Perinatal Infections Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Infection Type
        • 9.3.3.2.2.By Treatment
        • 9.3.3.2.3.By Diagnosis
        • 9.3.3.2.4.By End user

10.Market Dynamics

  • 10.1.Drivers
  • 10.2.Challenges

11.Market Trends Developments

  • 11.1.Recent Developments
  • 11.2.Product Launches
  • 11.3.Mergers Acquisitions

12.Global Perinatal Infections Market: SWOT Analysis

13.Porter's Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Product

14.Competitive Landscape

  • 14.1.Merck KGaA
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Product Services
    • 14.1.5.Financials (In case of listed)
    • 14.1.6.Recent Developments
    • 14.1.7.SWOT Analysis
  • 14.2.Beckman Coulter Inc.
  • 14.3.Bio-Rad Laboratories, Inc
  • 14.4.Hologic Inc.
  • 14.5.Gilead Sciences, Inc.
  • 14.6.Emcure Pharmaceuticals Limited.
  • 14.7.Cipla Inc.
  • 14.8.Bausch Health Companies Inc
  • 14.9.Johnson Johnson
  • 14.10.Teva Pharmaceutical Industries Ltd.

15.Strategic Recommendations

16. About Us Disclaimer